Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Thursday as it is currently trading at $20.14, above its previous 52-week high of $20.05 with 624,316 shares traded as of 11:35 a.m. ET. Average volume has been 2.8 million shares over the past 30 days.
Ariad has a market cap of $3.17 billion and is part of the
industry. Shares are up 63.2% year to date as of the close of trading on Wednesday.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
TheStreet Ratings rates Ariad as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full
52-week high stocks
or get investment ideas from our